Methodology of Gliclazide Detection in Biological Samples

Authors

  • Serhii I. Merzlikin National University of Pharmacy. Drug and Analytical Toxicology Department
  • Tetyana V. Kucher National University of Pharmacy. Drug and Analytical Toxicology Department
  • Krystyna Yu. Netosova National University of Pharmacy. Drug and Analytical Toxicology Department
  • Dmytro S. Kharchenko Ukrainian Military Medical Academy

Keywords:

gliclazide, analytical methods of research, chemical-toxicological analysis

Abstract

Aim: This research is dedicated to development of a methodology for the determination of gliclazide in biological samples for analytical diagnostics of lethal overdose caused by the drug.

Materials and Methods: TLC method: chromatographic plates Merck silica gel 60 F254 10×10 cm in size, mobile phase - ethyl acetate, visualization reagent 1% vanillin solution or 5% solution of chloral hydrate. HPLC method: liquid chromatograph «Milichrom-A-02» with UV detecting (RF); Prontosil-120-5-C18-AQ reverse-phase column Ø2×75 mm in diameter, 5 µm grains (Bischoff Analysetechnik und Geräte GmbH, Germany); Gradient elution with a mixture of two eluents (eluent A – [0.2 M solution LiClO4 – 0.005 M solution of HClO4] and eluent B - acetonitrile); Wavelength 230 nm.

Results: Methodology for the determination of gliclazide in biological samples is developed. It includes an effective method of gliclazide isolation from the objects of the study, specific and selective chromatographic detection methods and quantitative determination of toxicity in the extracts that had been received. It was established that while using TLC method gliclazide was assigned an Rf value of 0,48±0,01; detection limit is 3.0 µg. When applying HPLC method gliclazide holding time was 7.80 min (RSD = 0.13%), detection limit was 0.050 µg / ml, limit of the quantitative determination was 0.157 µg/ml, linearity of the procedure was in the range of 0.1-20.0 µg/ml. Under the developed conditions, gliclazide was determined at 17.48 ± 1.32 µg/ml (RSD = 6.06%).

Conclusions: Results of the study indicate that methodology for the determination of gliclazide in biological samples that was developed can be used for analytical diagnostics of lethal overdose caused by the drug.

Downloads

Download data is not yet available.

References

Pekareva EV. Advantages Gliclazide MB usage in patients with type 2 diabetes mellitus. Problems of endocrinology 2012; 58: 58-61.

Smirnova OM, Kononenko IV. Usage of Diabeton MV in the treatment of type 2 diabetes mellitus and prevention of its late complications. Pharmateca 2011; 16: 30-36.

Side_effects – [Electronic resource]. – 2015. – Access: http: //patientaville.com.

Kucher TV, Merzlikin SI, Kovalenko EV. Chromatographic detection of glibenclamide in biological objects in the modeling of combined poisonings with drugs. Bulletin of Pharmacy 2016; 1: 28-33.

Levine M, Ruha A, Lovecchio F. Hypoglycemia after accidental pediatric sulfonylurea ingestions. Pediatr Emerg Care 2011; 27: 846-49.

Gul M, Cander B, Girisgin S. The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose. Adv Ther 2006; 23: 878-84.

Kucher TV, Merzlikin SI, Schtrigol SY. Investigation of the distribution of glibenclamide in animal organs in the design of acute intoxication. ScienceRise 2016; 3: 7-12.

Kartashov VA. Chemico-toxicological analysis. P. 1. Isolation of toxic substances from biological objects. Maikop: «Quality Ltd.», 2008.

Downloads

Published

2018-06-20

How to Cite

1.
Merzlikin SI, Kucher TV, Netosova KY, Kharchenko DS. Methodology of Gliclazide Detection in Biological Samples. Ars Pharm [Internet]. 2018 Jun. 20 [cited 2024 Jul. 22];59(2):85-90. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/7516

Issue

Vol. 59 No. 2 (2018)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).